<center id="llk4z"><strong id="llk4z"></strong></center><rt id="llk4z"></rt>

QNZ NEW

Price	$36	$52	$85
Package	1mg	2mg	5mg

Min. Order:
Supply Ability:	10g
Update Time:	2025-06-11

Product Details

Product Name: QNZ	CAS No.: 545380-34-5
Purity: 99.86%	Supply Ability: 10g
Release date: 2025/06/11

Product Introduction

Bioactivity

Name	QNZ
Description	QNZ (EVP4593) (EVP4593) is an effective inhibitor of NF-κB activation and TNF-α production. The IC50 of QNZ for NF-κB and TNF-α is11 nM and 7 nM, respectively.
In vitro	Intraperitoneal injection of EVP4593 (1 mg/kg) in rats suppressed carrageenan-induced paw edema in a dose-dependent manner.
In vivo	In murine spleen cells stimulated by lipopolysaccharide, EVP4593 (IC50= nM) inhibits the production of TNF-α. In rat neutrophils, EVP4593 (10 nM) suppresses the upregulation of CSE expression induced by lipopolysaccharide. EVP4593 (40 nM) entirely inhibits the increase in the number and length of axons during laminin treatment in Schwann cell adhesion. Additionally, in IB4-negative neurons, EVP4593 (100 nM) blocks the induction effect of GRO/KC on K currents.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 5 mg/mL (14.03 mM), Sonication is recommended.
Keywords	Tumor Necrosis Factor Receptor \| TNF-α \| TNFR \| TNF Receptor \| QNZ \| Nuclear factor-κB \| Nuclear factor-kappaB \| NF-κB \| NFκB \| NF-kB \| NFkB \| Inhibitor \| inhibit \| EVP-4593 \| EVP 4593 \| CAY-10470 \| CAY 10470
Inhibitors Related	Naringin dihydrochalcone \| Acetylcysteine \| Methylamine HCl \| Diethylmaleate \| Glucosamine \| sodium lauroyl-α-hydroxyethyl sulfonate \| Lidocaine hydrochloride \| Apremilast \| N,N-Dimethylacetamide \| 5-Aminosalicylic Acid \| Lenalidomide \| Indole-3-carbinol
Related Compound Libraries	NF-κB Signaling Compound Library \| Bioactive Compound Library \| Membrane Protein-targeted Compound Library \| Anti-Breast Cancer Compound Library \| Antioxidant Compound Library \| Inhibitor Library \| Neuroprotective Compound Library \| Anti-Prostate Cancer Compound Library \| Anti-Cardiovascular Disease Compound Library \| Immunology/Inflammation Compound Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.